RhBNP therapy can improve clinical outcomes and reduce in-hospital mortality compared with dobutamine in heart failure patients: A meta-analysis

British Journal of Clinical Pharmacology

Volumn 81, Issue 1, 2016, Pages 174-185

  Lv, Ming Yi ^a   Deng, Shu Ling ^a   Long, Xiao Feng ^a  

^a DALIAN UNIVERSITY   (China)

Author keywords

Dobutamine; Heart failure; In hospital mortality; Meta analysis; Re admission; Recombinant human brain natriuretic peptide

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; RECOMBINANT PROTEIN;

ARTICLE; ASIAN; CAUCASIAN; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HOSPITAL READMISSION; HUMAN; META ANALYSIS; MORTALITY; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 84953370226     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12788     Document Type: Article

References (53)

1. Morrissey RP, Czer L, Shah PK. Chronic heart failure: current evidence, challenges to therapy, and future directions. Am J Cardiovasc Drugs 2011; 11: 153-71.
2. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K. Guidelines ESCCfP. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European society of cardiology. Developed in collaboration with the heart failure association of the ESC (HFA) and endorsed by the European society of intensive care medicine (ESICM). Eur J Heart Fail 2008; 10: 933-89.
3. Anguita M, Comin J, Almenar L, Crespo M, Delgado J, Gonzalez-Costello J, Hernandez-Madrid A, Manito N, Perez de la Sota E, Segovia J, Segura C, Alonso-Gomez AM, Anguita M, Cequier A, Comin J, Diaz-Buschmann I, Fernandez-Lozano I, Fernandez-Ortiz A, Gomez de Diego JJ, Pan M, Worner F, Alonso-Pulpon L, Bover R, Castro A, Diaz-Molina B, Gomez-Bueno M, Gonzalez-Juanatey JR, Lage E, Lopez-Granados A, Lupon J, Martinez-Dolz L, Munoz R, Pascual D, Ridocci F, Roig E, Varela A, Vazquez de Prada JA. Comments on the ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed) 2012; 65: 874-8.
4. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics-2014 update: a report from the American Heart Association Circulation 2014; 129: e28-e292.
5. Gielen S, Sandri M, Kozarez I, Kratzsch J, Teupser D, Thiery J, Erbs S, Mangner N, Lenk K, Hambrecht R, Schuler G, Adams V. Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig exercise intervention in chronic heart failure and aging catabolism study. Circulation 2012; 125: 2716-27.
6. Bui AL, Horwich TB, Fonarow GC. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011; 8: 30-41.
7. Kitzman DW, Nicklas B, Kraus WE, Lyles MF, Eggebeen J, Morgan TM, Haykowsky M. Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol 2014; 306: H1364-70.
8. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC. Get With the Guidelines Scientific Advisory C, InvestigatorsTrends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126: 65-75.
9. Cubbon RM, Gale CP, Kearney LC, Schechter CB, Brooksby WP, Nolan J, Fox KA, Rajwani A, Baig W, Groves D, Barlow P, Fisher AC, Batin PD, Kahn MB, Zaman AG, Shah AM, Byrne JA, Lindsay SJ, Sapsford RJ, Wheatcroft SB, Witte KK, Kearney MT. Changing characteristics and mode of death associated with chronic heart failure caused by left ventricular systolic dysfunction: a study across therapeutic eras. Circ Heart Fail 2011; 4: 396-403.
10. Casas JP, Kwong J, Ebrahim S. Telemonitoring for chronic heart failure: not ready for prime time. Cochrane Database Syst Rev 2011; 2011: ED000008.
11. Schiffer AA, Smith OR, Pedersen SS, Widdershoven JW, Denollet J. Type D personality and cardiac mortality in patients with chronic heart failure. Int J Cardiol 2010; 142: 230-5.
12. Zhao F, Chaugai S, Chen P, Wang Y, Wang DW. Effect of Nicorandil in patients with heart failure: A systematic review and meta-analysis. Cardiovasc Ther 2014; 32: 283-96.
13. Paraskevaidis IA, Ikonomidis I, Papadopoulos C, Stasinos V, Parissis J, Anastasiou-Nana M, Lekakis J. Dobutamineinduced changes of multidimensional cardiac deformation predict functional capacity in patients with advanced systolic heart failure. Int J Cardiol 2014; 176: 1438-40.
14. Fox PR, Oyama MA, Hezzell MJ, Rush JE, Nguyenba TP, DeFrancesco TC, Lehmkuhl LB, Kellihan HB, Bulmer B, Gordon SG, Cunningham SM, MacGregor J, Stepien RL, Lefbom B, Adin D, Lamb K. Relationship of plasma Nterminal pro-brain natriuretic peptide concentrations to heart failure classification and cause of respiratory distress in dogs using a 2nd generation ELISA assay. J Vet InternMed 2015; 29: 171-9.
15. Tacon CL, McCaffrey J, Delaney A. Dobutamine for patients with severe heart failure: a systematic review and metaanalysis of randomised controlled trials. Intensive Care Med 2012; 38: 359-67.
16. Partovian C, Gleim SR, Mody PS, Li SX, Wang H, Strait KM, Allen LA, Lagu T, Normand SL, Krumholz HM. Hospital patterns of use of positive inotropic agents in patients with heart failure. J Am Coll Cardiol 2012; 60: 1402-9.
17. den Uil CA, Lagrand WK, van der Ent M, Nieman K, Struijs A, Jewbali LS, Constantinescu AA, Spronk PE, Simoons ML. Conventional hemodynamic resuscitation may fail to optimize tissue perfusion: an observational study on the effects of dobutamine, enoximone, and norepinephrine in patients with acute myocardial infarction complicated by cardiogenic shock. PLoS One 2014; 9: e103978.
18. Bergh CH, Andersson B, Dahlstrom U, Forfang K, Kivikko M, Sarapohja T, Ullman B, Wikstrom G. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Eur J Heart Fail 2010; 12: 404-10.
19. Wang J, Yang H, Hu X, Fu W, Xie J, Zhou X, Xu W, Jiang H. Dobutamine-mediated heme oxygenase-1 induction via PI3 K and p38 MAPK inhibits high mobility group box 1 protein release and attenuates rat myocardial ischemia/reperfusion injury in vivo. J Surg Res 2013; 183: 509-16.
20. Barbosa MM, Freire CM, Nascimento BR, Rochitte CE, Silva MC, Siqueira MH, Nunes MC. Rest left ventricular function and contractile reserve by dobutamine stress echocardiography in peripartum cardiomyopathy. Rev Port Cardiol 2012; 31: 287-93.
21. Cataliotti A, Costello-Boerrigter LC, Chen HH, Textor SC, Burnett JC Jr Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension. Mayo Clin Proc 2012; 87: 413-5.
22. Zhao Q, Wu TG, Lin Y, Li B, Luo JY, Wang LX. Low-dose nesiritide improves renal function in heart failure patients following acute myocardial infarction. Heart Vessels 2010; 25: 97-103.
23. Vink S, Jin AH, Poth KJ, Head GA, Alewood PF. Natriuretic peptide drug leads from snake venom. Toxicon 2012; 59: 434-45.
24. Ren B, Wu H, Yin R, Xu L, Jing H, Li M, Jiang F, Wang Z. B-type natriuretic peptide pretreatment attenuates heart ischemia-reperfusion injury in rats. Transplant Proc 2010; 42: 4496-8.
25. Wang S, Qu X, Qu Y, Yu Y, Feng W. The effect of B-type brain natriuretic peptide on patients with acute decompensated heart failure coexisting with lung cancer: a randomized controlled clinical trial. Pharmazie 2014; 69: 212-6.
26. Zhang J, Fu X, Jia X, Fan X, Gu X, Li S, Wu W, Fan W, Su J, Hao G, Jiang Y, Xue L. B-type natriuretic peptide for prevention of contrast-induced nephropathy in patients with heart failure undergoing primary percutaneous coronary intervention. Acta Radiol 2010; 51: 641-8.
27. Kramer DB. Nesiritide in acute decompensated heart failure. N Engl J Med 2011; 365: 1547; discussion.
28. Tuy T, Peacock WF. Fluid overload assessment and management in heart failure patients. Semin Nephrol 2012; 32: 112-20.
29. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32-43.
30. Gheorghiade M, Pang PS, O'Connor CM, Prasad K, McMurray J, Teerlink JR, Fiuzat M, Sabbah H, Komajda M. Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for amechanistic translational phase. Am Heart J 2011; 161: 224-32.
31. Pan HY, Zhu JH, Gu Y, Yu XH, Pan M, Niu HY. Comparative effects of recombinant human brain natriuretic peptide and dobutamine on acute decompensated heart failure patients with different blood BNP levels. BMC Cardiovasc Disord 2014; 14: 31.
32. Pleister AP, Baliga RR, Haas GJ. Acute study of clinical effectiveness of nesiritide in decompensated heart failure: nesiritide redux. Curr Heart Fail Rep 2011; 8: 226-32.
33. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC, Jr., Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B, American College of C, American Heart Association Task Force on Practice G, American College of Chest P, International Society for H, Lung T, Heart Rhythm S. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American college of cardiology/American heart association task force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American college of chest physicians and the international society for heart and lung transplantation: endorsed by the heart rhythm society. Circulation 2005; 112: e154-235.
34. Chen H, Manning AK, Dupuis J. A method of moments estimator for random effect multivariate meta-analysis. Biometrics 2012; 68: 1278-84.
35. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005; 28: 123-37.
36. Zintzaras E, Ioannidis JP. HEGESMA: genome search metaanalysis and heterogeneity testing. Bioinformatics 2005; 21: 3672-3.
37. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-58.
38. Sterne JA, Egger M. Funnel plots for detecting bias in metaanalysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.
39. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
40. Zhang W. Clinical analysis of recombinant human brain natriuretic peptide treatment of after acute myocardial infarction decompensated heart failure. Cardiovasc Dis Prev Knowl Mag 2015; 93-4.
41. Fu XP, Li MQ, Chen MH, Zhang CY, Bao XJ, Lu WH, Wu XQ. Efficacy of recombinant human B-type natriuretic peptide on acute heart failure caused by acute myocardial infarction. Journal of Southeast University(Philosophy and Social Science) 2012; 31: 93-6.
42. Gerhard T, Zineh I, Winterstein AG, Hartzema AG. Pharmacoeconomic modeling of nesiritide versus dobutamine for decompensated heart failure. Pharmacotherapy 2006; 26: 34-43.
43. Arnold LM, Crouch MA, Carroll NV, Oinonen MJ. Outcomes associated with vasoactive therapy in patients with acute decompensated heart failure. Pharmacotherapy 2006; 26: 1078-85.
44. de Lissovoy G, Stier DM, Ciesla G, Munger M, Burger AJ. Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure. Am J Cardiol 2003; 92: 631-3.
45. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure. J Am Coll Cardiol 2002; 39: 798-803.
46. Burger AJ, Elkayam U, Neibaur MT, Haught H, Ghali J, Horton DP, Aronson D. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001; 88: 35-9.
47. Nakajima-Takenaka C, Sakata S, Kato S, Ohga Y, Murata KY, Taniguchi S, Takaki M. Detrimental effects after dobutamine infusion on rat left ventricular function: mechanical work and energetics. Exp Physiol 2005; 90: 635-44.
48. Dickey DM, Potter LR. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation. J Mol Cell Cardiol 2011; 51: 67-71.
49. Kogler H, Schott P, Toischer K, Milting H, Van PN, Kohlhaas M, Grebe C, Kassner A, Domeier E, Teucher N, Seidler T, Knoll R, Maier LS, El-Banayosy A, Korfer R, Hasenfuss G. Relevance of brain natriuretic peptide in preload-dependent regulation of cardiac sarcoplasmic reticulum Ca2+ ATPase expression. Circulation 2006; 113: 2724-32.
50. Mónica F, Murad F, Bian K. Modulating cGMP levels as therapeutic drug targets in cardiovascular and noncardiovascular diseases. OA Biochemistry 2014; 2: 3.
51. Liu SQ, Xie HW, Yan HY, Lu YQ, Wang LX. Recombinant B-type natriuretic peptide nesiritide attenuates vascular remodelling by reducing plasma aldosterone in rabbits. Heart Lung Circ 2012; 21: 551-5.
52. Saito Y. Roles of atrial natriuretic peptide and its therapeutic use. J Cardiol 2010; 56: 262-70.
53. Zhang J, Zhang L, Wu Q, Liu H, Huang L. Recombinant human brain natriuretic peptide therapy combined with bone mesenchymal stem cell transplantation for treating heart failure in rats. Mol Med Rep 2013; 7: 628-32.